drugset / Trial / NCT00695396
A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion
Phase 3
Terminated
25 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Centocor Ortho Biotech Services, L.L.C. · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to demonstrate that Epoetin alfa treatment reduces red blood cell transfusions in anemic patients with myelodysplastic syndromes (MDS). Myelodysplastic syndromes are a group of disorders characterized by progressive bone marrow failure and an increased risk of development of leukemia.
Timeline
- Start
- 2008-06
- Primary completion
- 2010-01
- Completion
- 2010-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | epoetin alfa | Protein / enzyme biologic | 40000 iu | Subcutaneous |
| Subject | epoetin alfa | Protein / enzyme biologic | 80000 iu | Subcutaneous |